New hope for advanced cervical cancer: experimental combo enters phase 2 trial
NCT ID NCT07497074
First seen Apr 11, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This study tests a new drug called JSKN033 combined with standard chemotherapy, with or without another drug (bevacizumab), in people with advanced cervical cancer that has come back or spread. The goal is to see if the combination is safe and shrinks tumors. About 78 adults with persistent, recurrent, or metastatic cervical cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.